Colin Davenport

List of Publications by Year
in descending order

35	719	567281 15	552781 26
papers	citations	h-index	g-index

35	35	35	1519
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Changes in the Leptin to Adiponectin Ratio Are Proportional to Weight Loss After Meal Replacement in Adults With Severe Obesity. Frontiers in Nutrition, 2022, 9, .	3.7	3
2	Improved Quality of Life, Fitness, Mental Health and Cardiovascular Risk Factors with a Publicly Funded Bariatric Lifestyle Intervention for Adults with Severe Obesity: A Prospective Cohort Study. Nutrients, 2021, 13, 4172.	4.1	8
3	TRAIL inhibits oxidative stress in human aortic endothelial cells exposed to proâ€inflammatory stimuli. Physiological Reports, 2020, 8, e14612.	1.7	4
4	Long-Term Changes in Weight in Patients With Severe and Complicated Obesity After Completion of a Milk-Based Meal Replacement Programme. Frontiers in Nutrition, 2020, 7, 551068.	3.7	4
5	Changes in alanine aminotransferase in adults with severe and complicated obesity during a milk-based meal replacement programme. Nutrition and Metabolism, 2020, 17, 87.	3.0	4
6	Coronavirus and Obesity: Could Insulin Resistance Mediate the Severity of Covid-19 Infection?. Frontiers in Public Health, 2020, 8, 184.	2.7	53
7	Effects of a Milk-Based Meal Replacement Program on Weight and Metabolic Characteristics in Adults with Severe Obesity . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 197-205.	2.4	10
8	A review of the propriety of thyroid ultrasound referrals and their follow-up burden. Endocrine, 2019, 65, 595-600.	2.3	6
9	Activation of the non-canonical NF-Î¹B/p52 pathway in vascular endothelial cells by RANKL elicits pro-calcific signalling in co-cultured smooth muscle cells. Cellular Signalling, 2018, 47, 142-150.	3.6	7
10	RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain. Journal of Vascular Research, 2018, 55, 111-123.	1.4	9
11	The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease. Cardiovascular Endocrinology and Metabolism, 2018, 7, 28-33.	1.1	10
12	TRAIL attenuates RANKL-mediated osteoblastic signalling in vascular cell mono-culture and co-culture models. PLoS ONE, 2017, 12, e0188192.	2.5	11
13	RANKL promotes osteoblastic activity in vascular smooth muscle cells by upregulating endothelial BMP-2 release. International Journal of Biochemistry and Cell Biology, 2016, 77, 171-180.	2.8	31
14	Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. Vascular Pharmacology, 2016, 82, 30-40.	2.1	103
15	Low-dose hydrocortisone replacement is associated with improved arterial stiffness index and blood pressure dynamics in severely adrenocorticotrophin-deficient hypopituitary male patients. European Journal of Endocrinology, 2016, 174, 791-799.	3.7	21
16	The beneficial pleiotropic effects of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) within the vasculature: A review of the evidence. Atherosclerosis, 2016, 247, 87-96.	0.8	33
17	Physiological and health characteristics of ex-jockeys. Journal of Science and Medicine in Sport, 2016, 19, 283-287.	1.3	12
18	The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes. Journal of Diabetes Research, 2015, 2015, 1-6.	2.3	23

#	Article	IF	Citations
19	The effect of vitamin D supplementation on arterial stiffness in an elderly communityâ€“based population. Journal of the American Society of Hypertension, 2015, 9, 176-183.	2.3	23
20	The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. European Journal of Endocrinology, 2015, 173, 53-61.	3.7	17
21	Regulation of Thrombomodulin Expression and Release in Human Aortic Endothelial Cells by Cyclic Strain. PLoS ONE, 2014, 9, e108254.	2.5	17
22	A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance. Metabolism: Clinical and Experimental, 2013, 62, 34-38.	3.4	20
23	An altered hormonal profile and elevated rate of bone loss are associated with low bone mass in professional horse-racing jockeys. Journal of Bone and Mineral Metabolism, 2012, 30, 534-542.	2.7	58
24	The effect of exercise on osteoprotegerin and TNFâ€related apoptosisâ€inducing ligand in obese patients. European Journal of Clinical Investigation, 2012, 42, 1173-1179.	3.4	11
25	Identifying coronary artery disease in men with type 2 diabetes. Journal of Hypertension, 2011, 29, 2469-2475.	0.5	11
26	Hypoglycaemiaâ€induced myocardial infarction as a result of sulphonylurea misuse. Diabetic Medicine, 2011, 28, 876-879.	2.3	8
27	Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism: Clinical and Experimental, 2011, 60, 994-1000.	3.4	52
28	The prevalence of adrenal incidentaloma in routine clinical practice. Endocrine, 2011, 40, 80-83.	2.3	75
29	Hyperbaric Oxygen in the Treatment of a Diabetic Foot Ulcer. Foot and Ankle Specialist, 2011, 4, 45-48.	1.0	1
30	Charcot-Marie-Tooth Disease Complicating Type 2 Diabetes. Journal of the American Podiatric Medical Association, 2011, 101, 349-352.	0.3	6
31	â€œDead in bedâ€ a tragic complication of type 1 diabetes mellitus. Irish Journal of Medical Science, 2010, 179, 585-587.	1.5	8
32	Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2010, 26, 496-502.	4.0	27
33	Central pontine myelinolysis secondary to hypokalaemic nephrogenic diabetes insipidus. Annals of Clinical Biochemistry, 2010, 47, 86-89.	1.6	11
34	Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thrombosis Research, 2010, 126, e423-e427.	1.7	19
35	The impact of pancreas and kidney transplant on cardiovascular risk factors (analyzed by mode of) Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	3